<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01207908</url>
  </required_header>
  <id_info>
    <org_study_id>2010-1491</org_study_id>
    <nct_id>NCT01207908</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy</brief_title>
  <official_title>IGF-1 Therapy and Muscle Function in Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charley's Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether IGF-1 therapy improves or preserves muscle
      function in Duchenne Muscular Dystrophy (DMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description:

      DMD is a progressive degenerative muscle disorder for which there is no current cure.
      Glucocorticoids (GC) are often used to improve motor function and survival but have
      significant side effects such as growth failure, weight gain, insulin resistance and
      osteoporosis. IGF-1 stimulates both the proliferation and differentiation of skeletal muscle
      cells and is thus important for muscle repair and regeneration. IGF-1 offers potential as a
      therapeutic agent for DMD as it may improve or preserve motor function and reduce GC side
      effects such as growth failure and insulin resistance.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six Minute Walk Test (6MWT)</measure>
    <time_frame>6 months</time_frame>
    <description>IGF-1 treatment motor function assessment by the difference in the distance traveled using the 6MWT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Growth Rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in motor function</measure>
    <time_frame>6 months</time_frame>
    <description>Assessed by North Star Ambulatory Assessment, timed functional tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>6 months</time_frame>
    <description>Measuring pulmonary function, cardiac function, and safety labs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>IGF-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGF-1 plus standard steroid treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard steroid treatment alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IGF-1</intervention_name>
    <description>IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.</description>
    <arm_group_label>IGF-1</arm_group_label>
    <other_name>Increlex (mecasermin [rDNA origin] injection)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard steroid treatment</intervention_name>
    <description>Will complete all study related procedures and evaluations</description>
    <arm_group_label>Standard steroid treatment alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DMD diagnosed with mutational testing and/or complete absence of dystrophin on muscle
             biopsy

          -  Proximal pelvic girdle weakness (Gower's maneuver, difficulty with arising from floor
             and going up steps)

          -  Male

          -  Age &gt; 5 years of age

          -  Bone maturation (assess by bone age x-ray): &lt;/= 11 years of age

          -  Daily GC (prednisone or deflazacort) therapy for &gt; 12 months

          -  Ambulatory

          -  Informed consent

          -  Willingness and ability to comply with all protocol requirements and procedures

        Exclusion Criteria:

          -  Current or prior treatment with growth hormone or IGF-1 therapy

          -  Non-ambulatory

          -  Pubertal (based on clinical Tanner staging examination)

          -  Congestive cardiac failure

          -  History of intracranial hypertension

          -  Daytime ventilatory dependence (non-invasive or tracheostomy)

          -  Concomitant therapy - any other medications/supplements that would be considered, in
             the opinion of the investigators, to affect muscle function, need to have been started
             3 months prior to enrollment

          -  Patients enrolled in other clinical drug trials

          -  Any physical or mental conditions which may, in the investigators'opinions, render the
             subject unable to complete the tasks of the study appropriately

          -  There will be no selection by ethnicity
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meilan Rutter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ghr.nlm.nih.gov/</url>
    <description>Genetics Home Reference</description>
  </link>
  <link>
    <url>http://ghr.nlm.nih.gov/condition/duchenne-and-becker-muscular-dystrophy</url>
    <description>Duchenne and Becker Muscular Dystrophy</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/musculardystrophy.html</url>
    <description>Muscular Dystrophy</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/</url>
    <description>Medline</description>
  </link>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2010</study_first_submitted>
  <study_first_submitted_qc>September 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2010</study_first_posted>
  <last_update_submitted>June 12, 2012</last_update_submitted>
  <last_update_submitted_qc>June 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DMD</keyword>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>Insulin like growth factor</keyword>
  <keyword>6 minute walk test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mecasermin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

